GURU.Markets stock price, segment price, and overall market index valuation
The company's share price bluebird bio Inc.
Bluebird Bio is a pioneering company in gene therapy. Its stock price is a dramatic story of scientific breakthroughs, regulatory setbacks, and successes. Its share price reflects both the enormous potential of its approved drugs and the high cost and complexity of this type of treatment.
Share prices of companies in the market segment - Dna
Bluebird Bio is a leading gene therapy company developing treatments for rare genetic diseases and certain types of cancer. We've categorized it as a "DNA" company, and the chart below shows how the market views this disruptive yet risky biotech sector.
Broad Market Index - GURU.Markets
Bluebird Bio is a biotechnology company, a pioneer in gene therapy for rare and severe genetic diseases. As a component of the GURU.Markets index, it is at the forefront of science. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BLUE - Daily change in the company's share price bluebird bio Inc.
Bluebird Bio, Inc.'s daily price change reflects the extreme volatility inherent in gene therapy companies. This metric is a measure of its sensitivity to FDA approvals and the commercial success of its expensive drugs.
Daily change in the price of a set of shares in a market segment - Dna
Bluebird Bio is a pioneer in gene therapy for the treatment of severe genetic diseases. This sector is one of the most advanced and volatile in biotechnology. The chart below reflects the extreme fluctuations typical of this industry, where news can dramatically change a company's valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Bluebird Bio is a pioneer in gene therapy. The company's shares are known for their extreme volatility, driven by both breakthroughs in rare disease treatments and setbacks. This is a prime example of how a single story can create powerful market ripples.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization bluebird bio Inc.
Bluebird Bio, Inc.'s year-over-year performance is a story of the transition from development to commercial gene therapy. Its market cap growth over the past 12 months reflects FDA approvals for its drugs for rare genetic diseases. Its valuation is a bet on its ability to successfully commercialize these complex and expensive treatments.
Annual dynamics of market capitalization of the market segment - Dna
Bluebird Bio, Inc. is a pioneering gene therapy company. Following its restructuring, it has focused on commercializing its approved drugs. This chart shows how the market perceives its ability to successfully market its expensive but revolutionary drugs and its path to profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bluebird Bio, a gene therapy pioneer developing one-time treatments for severe genetic diseases, exemplifies breakthrough science. Its annual market capitalization is extremely volatile compared to the market, depending on regulatory decisions and its ability to demonstrate the long-term efficacy and safety of its methods.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization bluebird bio Inc.
Bluebird Bio is a pioneer in gene therapy. Its monthly performance is extremely volatile and depends entirely on the regulatory and commercial success of its expensive drugs. News about FDA approvals and the pace of hospital rollouts are the main events.
Monthly dynamics of market capitalization of the market segment - Dna
Bluebird Bio is a pioneering company in the field of gene therapy. Its path has been full of dramatic ups and downs, driven by trial results and regulatory decisions. The chart below vividly illustrates the high volatility and risks of the entire gene therapy sector, where the stakes are incredibly high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bluebird Bio is a pioneering company in the field of gene therapy. Its history is full of ups and downs. Its stock price is entirely dependent on advances in the treatment of rare genetic diseases, regulatory decisions, and the ability to commercialize very expensive treatments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization bluebird bio Inc.
Shares of Bluebird Bio, a pioneer in gene therapy, are extremely volatile. Weekly price movements depend entirely on news about clinical trials, FDA regulatory decisions, and the commercial success of their approved, but very expensive, drugs. The chart below is a clear example of how short-term events in cutting-edge medicine influence stock prices.
Weekly dynamics of market capitalization of the market segment - Dna
Bluebird Bio is a pioneer in gene therapy. The company achieved approval for its drugs but faced commercial challenges. Its stock chart tells the story of how scientific success doesn't always guarantee market success. Compare its path to the pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bluebird Bio is a pioneer in gene therapy. This chart compares its highly volatile weekly performance with the market. It shows how its shares are driven by news about regulatory decisions, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
BLUE - Market capitalization of the company bluebird bio Inc.
The valuation chart of bluebird bio, Inc. tells the dramatic story of one of the pioneers of gene therapy. The company's market capitalization reflects both its scientific triumphs—the approval of several drugs for rare diseases—and the enormous commercial challenges associated with the high cost and complexity of its treatments.
BLUE - Share of the company's market capitalization bluebird bio Inc. within the market segment - Dna
Bluebird Bio's market share in DNA technologies reflects its status as a pioneer in gene therapy. Its market weight is reflected in its approved drugs for rare genetic diseases and its complex development path, which highlights both the enormous potential and challenges of this cutting-edge field of medicine.
Market capitalization of the market segment - Dna
Take a look at the chart: this is the total market capitalization of gene therapy companies. Bluebird Bio is one of the pioneers and most well-known names. The dynamics on the chart reflect both the enormous scientific breakthroughs and the commercial challenges and high costs of these revolutionary treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with rare genetic diseases. Bluebird Bio's market capitalization reflects the valuation of its highly complex and expensive gene therapy. The line shows the rollercoaster of commercialization for breakthrough science, which is vying for its share of the future of medicine.
Book value capitalization of the company, segment and market as a whole
BLUE - Book value capitalization of the company bluebird bio Inc.
Bluebird Bio's book value represents its scientific and production capital. The chart below reflects the valuation of its patents for gene therapy platforms for rare genetic diseases. Growth in the pipeline signifies progress in securing approvals and commercializing these complex and life-saving treatments.
BLUE - Share of the company's book capitalization bluebird bio Inc. within the market segment - Dna
Bluebird Bio's core assets are its R&D centers and, more importantly, its production facilities for creating personalized gene therapies. The chart shows the company's share of this complex and capital-intensive biotech infrastructure, which is key to treating rare genetic diseases.
Market segment balance sheet capitalization - Dna
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Bluebird Bio, a pioneer in gene therapy, has a hybrid model. Its value lies in its science, but to produce its complex drugs, it builds its own capital-intensive factories.
Book value of all companies included in the broad market index - GURU.Markets
Bluebird Bio is a pioneer in gene therapy. The company's assets include unique manufacturing processes for creating "living drugs" that can cure rare genetic diseases in a single procedure. The chart below illustrates the financial weight behind this highly complex medical technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - bluebird bio Inc.
Bluebird Bio is a pioneer in gene therapy. Its assets include unique and highly expensive, yet potentially curative, treatments for rare diseases. The chart below tells a story of tremendous scientific achievements and commercial challenges. This dynamic reflects the company's belief in making its therapies accessible and profitable.
Market to book capitalization ratio in a market segment - Dna
Bluebird Bio, Inc. is a pioneer in gene therapy. Its value is based on its revolutionary, yet complex and expensive, technology. This chart shows how its market valuation, reflecting both its enormous potential and high risks, relates to its book value.
Market to book capitalization ratio for the market as a whole
Bluebird Bio is a pioneer in gene therapy. This chart shows how the market values its approved drugs for rare genetic diseases and the associated high risks and potential rewards. The valuation reflects confidence in the future of genetic engineering.
Debts of the company, segment and market as a whole
BLUE - Company debts bluebird bio Inc.
Bluebird Bio, a pioneer in gene therapy, is managing its balance sheet amid extremely high R&D and commercial launch costs for its drugs. This chart shows how the company, with approved but very expensive treatments, is struggling to build a sustainable commercial model and fund future research.
Market segment debts - Dna
Bluebird Bio is a pioneering company in gene therapy. This chart shows how its high debt load reflects the enormous R&D and commercialization costs of its extremely expensive, yet potentially curative, drugs, a formidable challenge for even the most innovative biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio bluebird bio Inc.
BM Technologies is a fintech company that provides banking services through mobile apps, often in partnership with universities. The chart shows how the company funds the development of its technology platform and marketing to attract users in the competitive digital banking landscape.
Market segment debt to market segment book capitalization - Dna
Bluebird Bio is a biotech company pioneering gene therapy for treating severe genetic diseases. This chart compares its debt to the overall market capitalization of the entire sector. It shows how the company finances its extremely expensive research and development and commercialization of approved drugs.
Debt to book value of all companies in the market
Bluebird Bio, Inc. is a leading gene therapy company developing treatments for severe genetic diseases. This is a highly complex and very expensive technology. This chart of total market debt illustrates the environment in which Bluebird Bio is raising the enormous capital needed to bring its life-saving, but extremely expensive, drugs to market.
P/E of the company, segment and market as a whole
P/E - bluebird bio Inc.
This chart for Bluebird Bio, a gene therapy pioneer, shows a valuation based on its approved products. The P/E will depend on the highly complex and expensive commercialization process of its rare disease treatments. This is an assessment not only of the science but also of the company's ability to make it accessible to patients.
P/E of the market segment - Dna
Bluebird Bio is a leading gene therapy company. It develops and commercializes drugs to treat severe genetic diseases such as sickle cell anemia and beta thalassemia. This chart shows the overall valuation of the DNA technology sector, reflecting the premium investors are willing to pay for a potential cure for previously incurable diseases.
P/E of the market as a whole
Bluebird Bio is a leading gene therapy company developing drugs to treat severe genetic diseases. The company has several approved products. This risk appetite chart helps understand how investors view gene therapy pioneers, given their high potential and risks.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company bluebird bio Inc.
Bluebird Bio is a pioneer in gene therapy, developing treatments for rare genetic diseases. This graph reflects market expectations regarding the commercial success of its currently approved and future drugs. Profitability depends on a complex manufacturing process and cost reimbursement.
%20P%2FE%20bluebird%20bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-bluebird-bio-Inc.&v=1772638977039 "Chart of the company's future (projected) P/E bluebird bio Inc.")
Future (projected) P/E of the market segment - Dna
Bluebird Bio is a pioneer in gene therapy, developing drugs to treat severe genetic diseases. This chart shows how investors view its commercial prospects after receiving approvals for its high-priced drugs. It compares Bluebird Bio to other companies in the sector.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772638977112 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Bluebird Bio is a biotech company pioneering gene therapy for the treatment of severe genetic diseases. Its success depends on the approval and commercialization of highly expensive but potentially curative drugs. This chart, reflecting market optimism, demonstrates the investor appetite for risk required to finance such breakthrough technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772638977154 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit bluebird bio Inc.
Bluebird Bio is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. Its financial results reflect the transition from development to commercialization of its approved drugs. This chart illustrates the high costs associated with bringing complex and expensive treatments to market.
Profit of companies in the market segment - Dna
Bluebird Bio is a pioneer in gene therapy, developing drugs to treat severe genetic diseases. This graph, showing overall profitability in the sector, reflects the high risks and enormous potential of biotechnology. Successful approval and launch of Bluebird Bio's drugs could not only transform the lives of patients but also generate enormous profits for the entire industry.
Overall market profit
Bluebird Bio is a pioneer in the field of gene therapy. The company develops treatments for severe genetic diseases and certain types of cancer. Its path has been filled with both triumphs and setbacks, reflecting the complexity and risks at the forefront of science.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company bluebird bio Inc.
Bluebird Bio is a pioneer in gene therapy for rare genetic diseases. Future revenue projections depend on the successful commercialization of its approved drugs and the approval of new ones.
%20profit%20of%20the%20company%20bluebird%20bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-bluebird-bio-Inc.&v=1772638977260 "Graph of future (projected) profit of the company bluebird bio Inc.")
Future (predicted) profit of companies in the market segment - Dna
Bluebird Bio is a pioneer in gene therapy, developing treatments for severe genetic diseases and certain types of cancer. This chart shows revenue projections for the gene therapy segment. It allows one to assess how the company's potentially revolutionary, but very expensive, treatments compare to financial expectations for this cutting-edge field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772638977311 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Bluebird Bio is a pioneer in gene therapy. The company develops treatments for severe genetic diseases. Its success is determined by scientific breakthroughs and regulatory approvals. This graph, reflecting the investment climate, is critically important, as gene therapy development requires significant investment, which is more readily available during periods of market growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772638977343 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - bluebird bio Inc.
Bluebird Bio is a pioneering gene therapy company developing treatments for severe genetic diseases. This chart, which compares market capitalization to initial revenue from approved drugs, reflects the high costs and challenges of commercialization. It shows how investors view the potential of its revolutionary, but very expensive, treatments.
P/S market segment - Dna
Bluebird Bio, Inc. is a biotechnology company pioneering gene therapy. The company develops and commercializes treatments for severe genetic diseases and certain types of cancer. This chart reflects the premium the market is willing to pay for revenue in the gene therapy sector, demonstrating confidence in the revolutionary potential of Bluebird Bio's technologies.
P/S of the market as a whole
Bluebird Bio is a biotech company pioneering gene therapy for the treatment of severe genetic diseases such as sickle cell anemia. This chart, showing the average valuation, highlights that investors value the company based on its groundbreaking scientific achievements.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company bluebird bio Inc.
Bluebird Bio is a biotech company pioneering gene therapy for the treatment of severe genetic diseases. This chart shows how investors value the company based on projected future sales of its approved drugs. It reflects their belief in the commercial success of these revolutionary, but very expensive, treatments.
%20P%2FS%20bluebird%20bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-bluebird-bio-Inc.&v=1772638977479 "The graph of the company's future (projected) P/S bluebird bio Inc.")
Future (projected) P/S of the market segment - Dna
Bluebird Bio is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. The chart shows average sales expectations for the DNA research sector. It provides insight into how investors assess the commercial potential of the company's already approved drugs and its ability to successfully bring complex and expensive treatments to market.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772638977487 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Bluebird Bio (BLUE) is a pioneer in gene therapy. They develop and commercialize drugs to treat severe genetic diseases. Their success depends on scientific breakthroughs and regulatory approvals, not economic cycles. This chart doesn't reflect their potential to change patients' lives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772638977523 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales bluebird bio Inc.
Bluebird Bio's revenue is generated in the cutting-edge field of gene therapy. The company sells highly complex and expensive drugs for the treatment of rare genetic diseases. While nonlinear, its growth reflects successful approvals and the healthcare system's ability to afford these revolutionary, yet very expensive, treatments.
Sales of companies in the market segment - Dna
Bluebird Bio is a biotechnology company pioneering gene therapy. Following the separation of its oncology business, its revenue will be generated from sales of its approved drugs for rare genetic diseases. This reflects its focus on this cutting-edge field of medicine.
Overall market sales
Bluebird Bio, Inc. is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. The company's success depends on the approval and commercialization of its highly expensive, yet potentially curative, therapies. This graph, reflecting the overall state of the economy, affects the ability of the healthcare system and insurance companies to pay for such revolutionary treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company bluebird bio Inc.
Bluebird Bio is a biotech pioneer in gene therapy for severe genetic diseases. This chart shows analysts' expectations for the commercial success of its approved, but very expensive, treatments.
%20sales%20of%20the%20company%20bluebird%20bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-bluebird-bio-Inc.&v=1772638977612 "Schedule of future (projected) sales of the company bluebird bio Inc.")
Future (projected) sales of companies in the market segment - Dna
Bluebird Bio, Inc. is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. This chart shows the outlook for the DNA research sector. It reflects the enormous potential and scientific breakthrough in treating rare diseases with a single administration of gene therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772638977647 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
This chart illustrates investment appetite in biotech, which is critical for bluebird bio. A pioneer in gene therapy, the company relies on its ability to finance extremely expensive research and obtain regulatory approval. Positive economic forecasts facilitate long-term investment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772638977719 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality bluebird bio Inc.
Bluebird Bio is a pioneer in gene therapy, developing drugs to treat severe genetic diseases. This graph reflects the complex commercialization of breakthrough technologies. Profitability depends on the successful launch of approved drugs, their high price, and reimbursement from insurance companies.
Market segment marginality - Dna
Bluebird Bio is a biotechnology company pioneering gene therapy for severe genetic diseases. Profitability depends on obtaining approvals and successfully commercializing its complex and expensive treatments. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the enormous potential and risks associated with its technologies.
Market marginality as a whole
Bluebird Bio is a pioneer in gene therapy, developing treatments for severe genetic diseases. The company's success depends on regulatory approval and the extremely high cost of its drugs. This price tag, reflecting the state of the economy, affects the ability of healthcare systems and insurance companies to cover revolutionary, but very expensive, treatments.
Employees in the company, segment and market as a whole
Number of employees in the company bluebird bio Inc.
Bluebird Bio, Inc. is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. This graph shows a team of highly specialized scientists and clinicians. The dynamics reflect the complex path from research to commercialization, including obtaining approvals and establishing manufacturing infrastructure.
Share of the company's employees bluebird bio Inc. within the market segment - Dna
Bluebird Bio is a pioneer in gene therapy, developing drugs to treat rare genetic diseases. This chart shows the percentage of leading scientists in this revolutionary field that the company employs. It reflects its scientific heritage and the complex manufacturing processes required to create such drugs.
Number of employees in the market segment - Dna
Bluebird Bio, Inc. is a biotechnology company pioneering gene therapy for the treatment of severe genetic diseases. This chart, showing employment in the genetic engineering (DNA) sector, is key. The growing number of genetic scientists in this cutting-edge field signals the advent of an era in which genetic diseases can be treated at a fundamental level.
Number of employees in the market as a whole
Bluebird Bio is a pioneer in gene therapy. Their treatments can cure rare genetic diseases, but they are very expensive. This overall employment chart reflects the healthcare system's ability to pay for such breakthroughs. Only in a strong economy can insurance companies and governments afford to cover the costs of multi-million-dollar therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company bluebird bio Inc. (BLUE)
Bluebird Bio (BLUE) is a pioneer in gene therapy. They develop drugs to treat rare genetic diseases. This is the quintessence of "intellectual capital." Their value comes from their R&D and patents. This metric reflects the enormous potential value of their approved and currently developing treatments.
%20of%20the%20company%20bluebird%20bio%20Inc.%20(BLUE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-bluebird-bio-Inc.-BLUE&v=1772638977975 "Chart of market capitalization per employee (in thousands of dollars) of the company bluebird bio Inc. (BLUE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Bluebird Bio is a pioneer in gene therapy. The company develops one-time treatments for severe genetic diseases. Its value lies in its cutting-edge science and potential to cure diseases. This chart clearly demonstrates that in the world of gene therapy, the entire market value can be created by a small team of brilliant scientists.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772638978028 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Bluebird Bio is a pioneer in gene therapy. The company develops treatments for severe genetic diseases and certain types of cancer. This chart shows an extremely high valuation per employee, as its market cap is based on the potential of its revolutionary technologies, which can cure diseases with a single injection, developed by an elite scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772638978053 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company bluebird bio Inc. (BLUE)
Bluebird Bio is a pioneering company in gene therapy. They are developing "one-shot drugs" to treat severe genetic diseases (such as beta thalassemia). This requires extremely complex R&D. This graph shows the "cost of innovation": the enormous costs (negative profit) per scientist, which must then be recouped by the exorbitant price of the therapy.
%20Chart%20bluebird%20bio%20Inc.%20(BLUE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-bluebird-bio-Inc.-BLUE&v=1772638978069 "Company Profit Per Employee (in thousands of dollars) Chart bluebird bio Inc. (BLUE)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Bluebird Bio is a biotech company specializing in gene therapy for the treatment of severe genetic diseases. This chart reflects the complex path from scientific discovery to commercialization. High R&D and production costs lead to negative values, but the successful launch of even one drug can dramatically change the financial picture.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772638978074 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Bluebird Bio (BLUE) is a biotechnology company pioneering gene therapy for rare genetic diseases (such as beta thalassemia). It is an R&D company with early commercial products. This metric reflects the company's ability to recoup its enormous R&D costs through the individual sales of extremely expensive (millions of dollars) treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772638978085 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee bluebird bio Inc. (BLUE)
Bluebird Bio is a company developing gene therapy for severe genetic diseases. Following the approval of their drugs, this graph shows the beginning of their commercialization. The high cost of gene therapy leads to very high revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-bluebird-bio-Inc.-BLUE&v=1772638978115 "Sales chart per company employee bluebird bio Inc. (BLUE)")
Sales per employee in the market segment - Dna
Bluebird Bio is a pioneer in gene therapy. They are developing (and already selling) one-shot treatments for rare genetic diseases (such as beta thalassemia). This chart demonstrates how productive their complex model (R&D + manufacturing + sales) is. It reflects their ability to sell these ultra-expensive (millions of dollars) therapies.
Sales per employee for the market as a whole
Piedmont Office Realty Trust (PDM) is a REIT that owns, manages, and develops high-end office buildings, primarily in major cities in the US Sun Belt. Like most REITs, Piedmont has a relatively small team. This chart shows how effectively the team manages its multi-billion-dollar office portfolio. Their goal is to maximize rental income and occupancy.
Short shares by company, segment and market as a whole
Shares shorted by company bluebird bio Inc. (BLUE)
Bluebird Bio (BLUE) is a pioneer in gene therapy. Despite approved drugs, the company struggles with high treatment costs and slow adoption. This chart shows the number of short positions. Short positions reflect doubts about the company's commercial success.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-bluebird-bio-Inc.-BLUE&v=1772638978338 "Short Shares Chart for the Company bluebird bio Inc. (BLUE)")
Shares shorted by market segment - Dna
Bluebird Bio (BLUE) is a gene therapy pioneer developing treatments for rare genetic diseases and cancer. The chart below shows the overall short position in the gene therapy sector. It illustrates investors' concerns about the complexity of production and the high cost of these treatments.
Shares shorted by the overall market
Bluebird Bio is a pioneer in gene therapy, one of the most expensive and complex areas of R&D. This chart reflects the overall market pessimism. Investors fear not only burning through cash on research but also that insurance systems won't cover their ultra-expensive drugs (costing millions) during a crisis.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator bluebird bio Inc. (BLUE)
Bluebird Bio (BLUE) is a pioneer in gene therapy for rare genetic diseases. The company has experienced ups and downs due to FDA approvals and production issues. This indicator measures the strength of these sharp fluctuations. It shows when investor enthusiasm (above 70) or disappointment (below 30) reaches extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-bluebird-bio-Inc.-BLUE&v=1772638978475 "RSI 14 indicator chart for the company's stock bluebird bio Inc. (BLUE)")
RSI 14 Market Segment - Dna
Bluebird Bio is a pioneer in gene therapy. The company develops treatments (Zynteglo, Skysona) that "correct" the genetic code to treat rare and severe blood and neurological diseases. This chart measures the collective excitement in the gene therapy sector. It helps understand whether the entire speculative segment is being oversold due to regulatory delays.
RSI 14 for the overall market
For bluebird bio, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BLUE (bluebird bio Inc.)
Bluebird Bio is a pioneer in gene therapy. The company develops single-dose treatments for rare genetic diseases (beta thalassemia, sickle cell anemia). This chart shows the analysts' average 12-month forecast. Their target price is an estimate of the commercial success of these ultra-expensive but breakthrough treatments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BLUE-bluebird-bio-Inc.&v=1772638978588 "A chart showing analyst consensus forecasts for the expected stock price. BLUE (bluebird bio Inc.)")
The difference between the consensus estimate and the actual stock price BLUE (bluebird bio Inc.)
Bluebird Bio (BLUE) is a gene therapy pioneer. The company has undergone a renaissance and is now focused on commercializing its FDA-approved, single-shot drugs for rare blood disorders. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this challenging commercial launch.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BLUE-bluebird-bio-Inc.&v=1772638978637 "A chart showing the difference between the consensus forecast and the actual stock price. BLUE (bluebird bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Bluebird Bio (BLUE) is a pioneer in gene therapy. The company has secured FDA approval for highly complex and extremely expensive treatments for rare genetic diseases (Zynteglo). This chart shows general expectations for the DNA technology sector, reflecting whether experts believe gene therapy is commercially viable.
Analysts' consensus forecast for the overall market share price
Bluebird Bio (BLUE) is a pioneer in gene therapy. They've created "one-shot drugs" that *cure* rare blood diseases (sickle cell anemia). This chart shows the overall risk appetite. It reflects how much investors believe the healthcare system is willing to pay millions of dollars for their breakthrough, but ultra-expensive, drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index bluebird bio Inc.
Bluebird Bio is a pioneer (and martyr) of gene therapy. They were the first to cure (potentially, permanently) rare, fatal blood diseases (Beta-thalassemia, CALD). Their signature technique is extremely complex and incredibly expensive (millions of dollars) one-time injections. This chart is a summary of their commercialization history, reflecting their (very slow) launch.
AKIMA Market Segment Index - Dna
Bluebird Bio is a gene therapy company. They develop one-time treatments for severe genetic diseases (such as sickle cell anemia) by editing a patient's DNA. This chart compares their composite index to the sector, showing how their DNA treatments compare to others.
The AKIM Index for the overall market
Bluebird Bio is a gene therapy pioneer. It has developed approved treatments for sickle cell anemia and beta thalassemia. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for the commercialization of ultra-expensive therapies.
